Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05520138 · ClinicalTrials.gov registry record
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
A clinical trial of Prostatic Neoplasms, Castration-Resistant, sponsored by Pfizer.
- Completed
- Registry status
- 5,506
- Enrollment target
- 1
- Study location
NCT05520138 is a study of Prostatic Neoplasms, Castration-Resistant that has completed, run by Pfizer. The registered enrollment target is 5,506 participants, above the 190-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (2798% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05520138, a study of Prostatic Neoplasms, Castration-Resistant, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 5,506 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone using the 100% Fee-For-Service Medicare claims data. The study will address the following objectives: Primary objective: To compare overall survival (OS) in patients with chemotherapy-naïve mCRPC who initiated enzalutamide vs. abiraterone Secondary objectives: * To compare OS in patients with chemotherapy-naïve mCRPC who received only enzalutamide without any subsequent therapy vs. abiraterone without any subsequent therapy * To compare treatment duration and time to subsequent therapy in chemotherapy-naïve mCRPC patients initiating enzalutamide vs. abiraterone
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone acetate
Study Locations (1)
New York
- Pfizer Inc - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,506 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05520138
The ClinicalTrials.gov registry entry for NCT05520138 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,506 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 190-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (2798% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.
NCT05520138 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05520138 about?
NCT05520138 is a clinical study titled "Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)". This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone using the 100% Fee-For-Service Medicare claims data. The study will add...
What is the current status of trial NCT05520138?
This trial is currently completed. The enrollment target is 5,506 participants. The study started on 2022-08-29. Estimated completion is 2023-06-30.
What conditions does trial NCT05520138 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.
What interventions are being tested in trial NCT05520138?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT05520138?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05520138 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms, Castration-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RECRUITING · Phase 1
-
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RECRUITING · Phase 1
-
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RECRUITING · Phase 4
-
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 3
-
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.